Medicamen Biotech Limited (BOM:531146)

Medicamen Biotech Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	312.64	37.59	147.86	207.79	38.25
Cash & Short-Term Investments	312.64	37.59	147.86	207.79	38.25
Cash Growth	731.63%	-74.57%	-28.84%	443.26%	-1.69%
Accounts Receivable	818.28	689	552.59	652.58	632.24
Other Receivables	-	246.2	223.43	219.83	196.18
Receivables	844.91	935.2	776.03	872.41	828.42
Inventory	700.8	621.37	593.75	450.57	270.1
Prepaid Expenses	-	1.72	1.57	0.65	7.35
Other Current Assets	378.99	49.62	76.73	102.21	86.26
Total Current Assets	2,237	1,645	1,596	1,634	1,230
Property, Plant & Equipment	840.92	863.62	909.52	917.59	921.18
Other Intangible Assets	5.72	7.42	8.98	8.98	3.6
Long-Term Deferred Tax Assets	31.68	28.3	25.15	18.8	4.96
Long-Term Deferred Charges	554.65	414.22	393.73	195.12	88.17
Other Long-Term Assets	49.58	12.45	12.19	11.07	8.65
Total Assets	3,720	2,972	2,946	2,785	2,257

Liabilities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	400.06	348.17	334.57	416.52	393.12
Accrued Expenses	12.26	97.48	68.45	53.3	37.81
Short-Term Debt	416.31	295.19	295.62	233.13	192.75
Current Portion of Long-Term Debt	-	5.21	2.94	15.26	14.47
Current Income Taxes Payable	25.86	33.24	40.63	37	42.64
Current Unearned Revenue	-	-	3.18	21.31	14.41
Other Current Liabilities	24.71	2.33	100.17	49.22	31.71
Total Current Liabilities	879.2	781.62	845.55	825.74	726.91
Long-Term Debt	61.53	37.34	12.56	8.7	50.74
Pension & Post-Retirement Benefits	-	17.77	14.63	13.16	10.98
Long-Term Deferred Tax Liabilities	-	-0.03	-	-	-
Other Long-Term Liabilities	23.66	4.27	2.93	3.45	3.62
Total Liabilities	964.38	840.98	875.67	851.03	792.24

Shareholders' Equity

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	135.63	127.15	127.15	126.51	122.17
Additional Paid-In Capital	-	1,023	1,023	978.73	677.05
Retained Earnings	-	963.08	907.67	825.38	687.82
Comprehensive Income & Other	2,620	5.21	-7.01	-12.14	-22.34
Total Common Equity	2,756	2,119	2,051	1,918	1,465
Minority Interest	-	11.98	18.92	15.66	-
Shareholders' Equity	2,756	2,131	2,070	1,934	1,465
Total Liabilities & Equity	3,720	2,972	2,946	2,785	2,257

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	477.84	337.74	311.12	257.09	257.96
Net Cash (Debt)	-165.19	-300.15	-163.26	-49.3	-219.71
Net Cash Growth	-	-	-	-	-
Net Cash Per Share	-12.18	-23.61	-12.90	-3.90	-17.98
Filing Date Shares Outstanding	11.76	12.71	12.71	12.65	12.22
Total Common Shares Outstanding	11.76	12.71	12.71	12.65	12.22
Working Capital	1,358	863.88	750.38	807.89	503.47
Book Value Per Share	234.32	166.62	161.30	151.65	119.89
Tangible Book Value	2,750	2,111	2,042	1,910	1,461
Tangible Book Value Per Share	233.84	166.04	160.60	150.94	119.60
Land	-	9.42	9.42	9.42	9.42
Buildings	-	374.91	373.19	371.88	370.28
Machinery	-	985.95	966.94	907.24	853.66

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 23, 2026

Data Sources Report a data error